Motoshi TAKAO

Prof. Dr. Motoshi TAKAO

Mie University, Tsu, Mie, Japan
orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2020 in Radiology
Verified
Journal Article
Closed access
THTakaaki Hasegawa
Takaaki Hasegawa
HTHaruyuki Takaki
Haruyuki Takaki
HKHiroshi Kodama
Hiroshi Kodama
TYTakashi Yamanaka
Takashi Yamanaka
ANAtsuhiro Nakatsuka
Atsuhiro Nakatsuka
KYKoichiro Yamakado
Koichiro Yamakado
Radiofrequency ablation of the lung provides a favorable 3-year overall survival rate of 84% for patients with otherwise surgically resectable colorectal lung metastases measuring 3 cm or smaller. Background Although radiofrequency ablation (RFA) is widely performed for the treatment of colorectal cancer (CRC) lung metastases, its efficacy for candidates with surgically resectable disease is...

31 May 2011 in Lung Cancer
Verified
Journal Article
Closed access
PDF file
NSNaohisa Suzawa
Naohisa Suzawa
MIMorihiro Ito
Morihiro Ito
SQShanlou Qiao
Shanlou Qiao
KUKatsunori Uchida
Katsunori Uchida
Motoshi TAKAOMotoshi TAKAO
Motoshi TAKAO
SMShuichi Murashima
Shuichi Murashima

1 March 2021 in Lung Cancer
Verified
Journal Article
Closed access
YOYoichi Ohtaki
Yoichi Ohtaki
Kimihiro ShimizuKimihiro Shimizu
Kimihiro Shimizu
HSHiroyuki Suzuki
Hiroyuki Suzuki
KSKenji Suzuki
Kenji Suzuki
MTMasahiro Tsuboi
Masahiro Tsuboi
MCMasayuki Chida
Masayuki Chida

1 November 2021 in Experimental Cell Research
Verified
Journal Article
Closed access
EMEri Matsuo
Eri Matsuo
TOTakayuki Okamoto
Takayuki Okamoto
AIAtsushi Ito
Atsushi Ito
Eiji KawamotoEiji Kawamoto
Eiji Kawamoto
KAKunihiro Asanuma
Kunihiro Asanuma
ASAkira Shimamoto
Akira Shimamoto

1 July 2003 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
Motoshi TAKAOMotoshi TAKAO
Motoshi TAKAO
KIKentarou Inoue
Kentarou Inoue
FWFumiaki Watanabe
Fumiaki Watanabe
KOKoji Onoda
Koji Onoda
TSTakatsugu Shimono
Takatsugu Shimono
IYIsao Yada
Isao Yada
Bronchorrhea is one of late complaints in patients with bronchioloalveolar carcinoma (BAC) and hampers their quality of life. Although an effective treatment for bronchorrhea in these patients has not been established, recently we have treated effectively one case of persistent bronchorrhea associated with clinical recurrent BAC with gefitinib (ZD1839, 'Iressa™'; AstraZeneca Japan; Osaka, Japan). A 63-year-old Japanese female had undergone left pneumonectomy with radical lymph node dissection (ND2a) for diffuse type bronchioloalveolar carcinoma originated in left lower lobe. Multiple pulmonary metastases in right lung were found one year after operation. Pulmonary metastatic lesion has grown and she complained of progressive symptoms of massive watery sputum and dyspnea, four years after operation. Although her symptom was getting worse in spite of routine treatment, it completely disappeared within 2 weeks of starting oral gefitinib. Thereafter, she has been symptom-free and shows good partial response on repeat scan after 9 months of oral gefitinib. The dramatic remission of persistent bronchorrhea by gefitinib in the presented case suggests that gefitinib might be a promising option for bronchioloalveolar carcinoma, particularly in cases with severe bronchorrhea. Although it is not possible to comment on whether the improvement came from tumor cell death itself or suppressive effect of mucin synthesis by the epidermal growth factor receptor-tyrosine kinase inhibitory action.

1 April 2002
Verified
Journal Article
Closed access
MCMing Cai
Ming Cai
KOKoji Onoda
Koji Onoda
Motoshi TAKAOMotoshi TAKAO
Motoshi TAKAO
IKImanaka-Yoshida Kyoko
Imanaka-Yoshida Kyoko
HSHideto Shimpo
Hideto Shimpo
IYIsao Yada
Isao Yada